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hydroxy-vitamin D deﬁciency, total body irradiation, and
growth hormone deﬁciencies. This report is a single insti-
tutions retrospective analysis of bone density evaluation and
incidence of OP/ON following pediatric SCT.
Method: From 2003 to 2012, 17 patients undergoing allo-
geneic stem cell transplantation (5 AML, 8 ALL, 1 CML, 1 NHL,
2 aplastic anemia) received lipid proﬁle evaluation per-
formed at Loma Linda University Medical Center by a Roche
Modular System Photometric Assay and 25-OH vitamin D
analysis at Mayo Clinic, Rochester Minnesota. 15 of these
patients also had bone density testing by a dual-energy x-ray
absorptiometry (DEXA) scan. With osteoporosis and osteo-
penia deﬁned as Z score <-1 and <-2.5 respectively. 9
patients received stem cells from HLA matched unrelated
donors (MUD) and 8 HLA matched related sibling donors
(MRD). Patients were treated with: (14) 1200 cGy total body
irradiation, 1500mg/m2 etoposide, 120 mg/kg cyclophos-
phamide; (1) busulfan (16 doses), 200 mg/kg cyclophos-
phamide; (2) ATG, 200 mg/kg cyclophosphamide, 200 cGy
total body irradiation. GVHD prophylaxis was cyclosporine
for MRD or tacrolimus for MUD and short course metho-
trexate. Patient's age at testing ranged from 7 to 23 years,
mean 13.5 years.
Result: OP was extremely common after SCT with bone
density Z score of lower then -1 in 13/15 tested. 25-OH Vit D
was low in 15 /17 tested. Elevated cholesterol was present in
8/17 and cholesterol/HDL ratio (>3.5%) in 12/15 tested.
Stratiﬁcation of patients by history of chronic GVHD or
moderate to severe acute GVHD showed that while meta-
bolic abnormality was present in both groups, symptomatic
OP/ON were conﬁned to the chronic GVHD group. Among 4
patients with no history of GVHD, 2/4 had normal bone
density, 2/4 had normal lipids, and none had symptomatic
OP/ON. In contrast, among 13 patients with GVHD all 10/10
tested had diminished bone density, 9/10 tested had elevated
lipid ratios, and 5/13 had symptomatic OP/ON with 4
requiring surgery. Symptomatic OP/ON events resulted in the
need for joint replacement of the knees, hips and shoulders.
In addition, patients had fractures of the long bones needing
internal ﬁxation devices to help with the repair.
Conclusion: These results suggest that lipid metabolism
abnormalities and low Vit D levels are common after SCT and
interventions to normalize these abnormalities may have the
greatest impact on symptomatic ON/OP in patients with
GVHD.210
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Background: Neurocognitive function is vulnerable in the
formative pediatric years to transplant conditioning regimen
especially those using fractionated total body irradiation
(FTBI). However, FTBI improves disease free survival (DFS) in
lymphoid malignancies. Our institution has previously
described a novel conditioning regimen using low dose
single fraction TBI (SDTBI) delivered at a high dose rate. DFS
was comparable to recipients of fractionated TBI, and early
toxicities were minimal (Druley, BMT 2009). Our hypothesisis that SDTBI based myeloablative conditioning is associated
with less neurotoxicity and can preserve neurocognitive
functions in children.
Aim: To review neurocognitive function in children
following SDTBI (550 cGy) and cyclophosphamide- based
myeloablative transplant conditioning for hematologic
malignancies pre and 1 year post transplant.
Methods: A total of 45 consecutive children transplanted for
hematologic malignancies (ALL, AML, NHL) between March
1998 and January 2006 that survived beyond 1 year after
transplant were identiﬁed. The conditioning regimen con-
sisted of cyclophophamide 50 mg/kg on days -3 and -2, and
SDTBI (550 cGy) on day -1. Fifteen had neurocognitive testing
completed before and at least 1 year post transplant. This
testing comprised of a comparative analysis of IQ and neu-
rocognitive function using Wechsler intelligence scales
selected based on the child's age.
Result: Full scale (FSIQ), verbal (VIQ), and performance or
non-verbal (PIQ) IQs were compared. Using a greater than 1
SD loss (or greater than 15 point loss) criterion as a gross
marker for signiﬁcant decline at the individual patient level.
Fifteen patients had an average age was 10.7 years (range 1-
20.5). No patient showed a decline in FSIQwith the exception
of one. This child underwent a second myeloablative trans-
plant one year after the ﬁrst; FSIQ declined by 16 points. One
child's VIQ declined 23 points; two others’ PIQ declined by 16
and 21 points, respectively.
Conclusion: Among a limited cohort of SDTBI BMT, the
majority showed an overall stability or lack of signiﬁcant
decline in neurocognitive function one year post transplant.
In contrast, previous reports show decline one year post
transplant in children receiving FTBI (Phipps S et al, JCO
2008; Shah et al, PBC 2008). These data provide an initial
insight into the effects of SDTBI based conditioning on neu-
rocognition in children. Future studies will expand the
analysis to further analyze exposure to CNS toxic treatments
and to examine more detailed cognitive measures for
domain speciﬁc trends. We will also look at patients that
received FTBI and Bulsulfan/cyclosphosphamide.211
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Introduction: Hematopoietic stem cell transplantation
(HSCT) is an increasingly utilized treatment option for
adolescents with a wide range of life-threatening diagnoses.
Following discharge, adolescents who have undergone HSCT
must manage a complex treatment regimen including
numerous oral and/or intravenous medications. Suboptimal
adherence to this medication regimen may result in sub-
therapeutic medication exposure, potentially compromising
treatment effectiveness and, subsequently, increasing the
risk of adverse medical outcomes. During adolescence,
individuals are increasingly likely to experience stressors
